KR950700754A - New drugs (NOVEL MEDICAMENT) - Google Patents

New drugs (NOVEL MEDICAMENT)

Info

Publication number
KR950700754A
KR950700754A KR1019940703281A KR19940703281A KR950700754A KR 950700754 A KR950700754 A KR 950700754A KR 1019940703281 A KR1019940703281 A KR 1019940703281A KR 19940703281 A KR19940703281 A KR 19940703281A KR 950700754 A KR950700754 A KR 950700754A
Authority
KR
South Korea
Prior art keywords
new drugs
novel medicament
medicament
novel
drugs
Prior art date
Application number
KR1019940703281A
Other languages
Korean (ko)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700754A publication Critical patent/KR950700754A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019940703281A 1992-03-19 1994-09-17 New drugs (NOVEL MEDICAMENT) KR950700754A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (en) 1992-03-19 1992-03-19 PREPARATION
PCT/DK1993/000098 WO1993018785A1 (en) 1992-03-19 1993-03-18 Novel medicament

Publications (1)

Publication Number Publication Date
KR950700754A true KR950700754A (en) 1995-02-20

Family

ID=8092684

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703281A KR950700754A (en) 1992-03-19 1994-09-17 New drugs (NOVEL MEDICAMENT)

Country Status (6)

Country Link
EP (1) EP0631504A1 (en)
JP (1) JPH07504669A (en)
KR (1) KR950700754A (en)
AU (1) AU3888793A (en)
DK (1) DK36492D0 (en)
WO (1) WO1993018785A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
KR0154880B1 (en) * 1992-06-15 1998-10-15 피터 알.셰어러 Glucagon-like peptide and insulinotropin derivatives
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DE19530865A1 (en) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
WO1999029336A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
DE69942307D1 (en) 1998-02-27 2010-06-10 Novo Nordisk As N-TERMINAL CHANGED GLP-1 ABÖMMLINGE
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1840134B1 (en) 1998-02-27 2016-04-13 Novo Nordisk A/S GLP-1 derivatives
EP1932535A3 (en) 1998-07-31 2008-10-29 Novo Nordisk A/S Stimulation of beta cell profileration
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
JP2002523466A (en) * 1998-08-28 2002-07-30 イーライ・リリー・アンド・カンパニー Method of administering insulinotropic peptide
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
JP4689833B2 (en) * 1998-12-22 2011-05-25 イーライ リリー アンド カンパニー Storage-stable formulation of glucagon-like peptide-1
JP2003519664A (en) * 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Transepithelial delivery of GLP-1 derivatives
DE60114996T2 (en) 2000-03-08 2006-08-10 Novo Nordisk A/S LOWERING OF THE SERUM CHOLESTEROL
DE60224284T2 (en) 2001-06-28 2008-12-18 Novo Nordisk A/S STABLE FORMULATION OF MODIFIED GLP-1
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
WO2007065156A2 (en) * 2005-12-02 2007-06-07 Nastech Pharmaceutical Company Inc. Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
KR101340354B1 (en) 2004-11-12 2013-12-11 노보 노르디스크 에이/에스 Stable formulations of peptides
EP2769990A3 (en) 2004-12-02 2015-02-25 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
WO2007061434A2 (en) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
EP2411054A2 (en) 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
JP2013506628A (en) 2009-09-30 2013-02-28 グラクソ グループ リミテッド Drug fusions and conjugates with extended half-life
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
EP2788027A2 (en) 2011-12-09 2014-10-15 Novo Nordisk A/S Glp-1 agonists
GB201308753D0 (en) * 2013-05-15 2013-06-26 Stichting Nl Kanker Inst Compounds and their use in therapy
TWI783890B (en) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1 compositions and uses thereof
CA3165359A1 (en) 2020-02-18 2021-07-22 Dorthe Kot Engelund Glp-1 compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
DE69027022T2 (en) * 1989-02-17 1996-11-28 Liposome Co Inc LIPID AUXILIARY SUBSTANCES AND LOCAL APPLICATION
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
ATE164852T1 (en) * 1990-01-24 1998-04-15 Douglas I Buckley GLP-1 ANALOGUE USABLE IN DIABETES TREATMENT

Also Published As

Publication number Publication date
DK36492D0 (en) 1992-03-19
JPH07504669A (en) 1995-05-25
EP0631504A1 (en) 1995-01-04
AU3888793A (en) 1993-10-21
WO1993018785A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
KR950700754A (en) New drugs (NOVEL MEDICAMENT)
NO942923L (en) drugs
DK0616523T3 (en) drugs
FI921060A (en) PHARMACEUTICAL AEROSOLFORMULERINGAR
FI922958A (en) PHARMACEUTICAL SAMMANSAETTNING
FI922252A (en) PHARMACEUTICAL SAMMANSAETTNING
FI922316A (en) PHARMACEUTICAL SAMMANSAETTNING
FR2649613B1 (en) VASO-ACTIVE MEDICINE
NO920067D0 (en) FORADDITIVE FOR DRUGS
DK229489A (en) PHARMACEUTICAL ORBATS
BR9305077A (en) Hypodemic syringe
FI923581A (en) PHARMACEUTICAL COMBINATIONSFORMATION
FI930882A (en) PHARMACEUTICAL FORM
NO923859D0 (en) DRUG
NO931831D0 (en) PHARMACEUTICAL MIXTURES
BR9306974A (en) Syringe
NO934145D0 (en) Pharmaceutical compounds
FI931251A (en) PHARMACEUTICAL FORM
IT8922216A0 (en) PHARMACEUTICAL SOLUTION
BR9303012A (en) SYRINGE
KR950704292A (en) Bicycylic Compounds with Pharmaceutical Activity
FI955605A0 (en) Aryling drug
NO306381B1 (en) Pharmaceutical ampoule
FI934317A0 (en) PHARMACEUTICAL SAMMANSAETTNINGAR, VILKA INNEHAOLLER EJ-JONISKA YTAKTIVA AEMNEN
TH13625EX (en) Asiologic glycoproteins - conjugated drugs

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid